Prospects for plasma protein products in China
- VernacularTitle:中国血浆蛋白制品的展望
- Author:
Changyong JIAN
1
;
Fangyu DONG
1
;
Chen CHEN
1
;
An ZHOU
1
;
Jiuyue ZHOU
1
;
Xue DONG
1
;
Cuiping ZHANG
1
;
Dianwei SONG
1
;
Bo ZHOU
1
;
Shan MA
1
Author Information
- Publication Type:Journal Article
- Keywords: plasma protein products; immunoglobulin; Von Willebrand factor complex; anti-inhibitor coagulant complex; human antithrombin Ⅲ; C1 esterase inhibitor
- From: Chinese Journal of Blood Transfusion 2022;35(2):227-232
- CountryChina
- Language:Chinese
- Abstract: Plasma protein products, essential drugs for various clinical diseases, are therapeutic biological products extracted from healthy human plasma. The research and development of new plasma protein products, led by United States and European, has been widely deepened and enhanced. Therefore, accelerating the development of new plasma protein products in China is of great significance. This review summarizes the research and development of plasma protein products that have been marketed abroad but have not produced in China, as well as analyzes the difficulties and prospects of the development of plasma protein products in China.
